Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MP0310 in Advanced Solid Tumors
NCT04049903Phase 1Completed
- Sponsor
- Molecular Partners AG
- Start
- Sep 2019
- Primary completion
- Jun 2022
- Modality
- Bispecific Antibodies, Carrier/Scaffold Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of MP0310 in solid tumor (3 arms), sponsored by Molecular Partners AG. Primary endpoints: Incidence of Adverse Events, Incidence of Dose-Limiting Toxicities and 2 more. Started Sep 2019; status: completed.
02
Drugs
MP0310
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04049903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04049903.